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Synopsis 
 
Blood pressure (BP) is a quantitative term and is highly variable from person to person. 
The normal blood pressure for an individual should be 120/80 mm Hg. According to 
WHO report, if the BP crosses the mark of 140/90 mm Hg, it is classified as the case of 
‘high blood pressure’ (hypertension). Several factors are responsible for the increase in 
blood pressure such as kidney diseases, obesity, insulin resistance, high alcohol intake, 
high salt intake, ageing etc. All these effects are additive in elevating BP. Genetic factors 
are also a serious cause of hypertension. One of the major causes of hypertension is the 
malfunctioning of the renin angiotensin system (RAS). RAS consists of a number of 
peptides that play important role in blood pressure regulation. However, the decapeptide 
angiotensin I (Ang I) and the octapeptide angiotensin II (Ang II) are of particular 
importance as they directly influence the blood pressure level. Ang I is a prohormone, 
which is converted to active hormone Ang II by the cleavage of terminal dipeptide (His-
Leu). This reaction is catalyzed by a zinc-dependant metalloenzyme known as 
‘angiotensin converting enzyme’ (ACE). Furthermore, ACE is also responsible for the 
elevation of blood pressure by cleaving the terminal dipeptide (Phe-Arg) of vasodilator 
hormone bradykinin (nonapeptide) to its inactive form (bradykinin 1-7). 
 
Figure 1. ACE-catalyzed conversion of Ang I to Ang II and bradykinin to bradykinin (1-
7). Formation of Ang II and depletion of bradykinin concentration result in the elevation 
of blood pressure. 
Therefore, inhibition of ACE is important for the treatment of hypertension. 
Captopril was the first orally active inhibitor of ACE synthesized in the year 1977 by 
Ondetti and Cushman. After this report, a number of ACE inhibitory antihypertensive 
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drugs such as enalaprilat, 
zofenoprilat, fosinoprilat etc. have 
been reported. Most of these drugs 
consist of a proline 
pharmacophore. 
Recent evidences suggest 
that hypertension and oxidative 
stress are related to each other and hypertension plays an important role in the 
pathogenesis of oxidative stress and inflammation. It has been shown that hypertension 
induces oxidative stress by activating NADPH oxidase, leading to the overproduction of 
superoxide anion (O2•-). These reactive superoxide anions interact with nitric oxide (•NO) 
to generate peroxynitrite (ONOO-), a highly reactive intermediate known to nitrate 
protein tyrosine residues and cause celluar damage. Furthermore, Ang II-induced 
endothelial dysfunction has been associated with increased production of peroxynitrite 
(PN). Therefore, antihypertensive drugs having antioxidant activity are important in the 
treatment of hypertension. It is known that captopril and zofenoprilat have significant 
antioxidant activity that may contribute to their better cardio- and endothelium-protective 
effects. As selenium compounds are generally better antioxidants than their sulfur 
analogues, it was thought worthwhile to synthesize the selenium analogues of captopril 
and various other related compounds and study their ACE inhibition and antioxidant 
properties. For studying the antioxidant properties of the synthesized compounds, 
inhibition of peroxynitrite (PN) mediated nitration reactions were used. PN is a well-
known reactive oxygen species (ROS) and reactive nitrogen species (RNS) that can 
indiscriminately nitrate the tyrosine residues of proteins and peptides. Therefore, 3-nitro-
tyrosine is known as a potential ‘bio-marker’ for nitrosative stress conditions.  
The thesis consists of six chapters. The first chapter gives a general introduction 
on hypertension and various factors that lead to hypertension. Role of the renin 
angiotensin system (RAS) in blood pressure regulation and the importance of ACE 
inhibitors in the treatment of hypertension are also discussed in this chapter. This chapter 
gives a brief introduction to oxidative stress and the protection of various organisms 
against the oxidants. This chapter contains discussion about the biochemical role of 
peroxyntrite and the interrelation between oxidative stress and hypertension. Treatment 
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of hypertension with ACE inhibitory drugs having antioxidant properties may provide a 
better recovery from hypertension. Antioxidant activity of selenium-containing 
compounds and a comparison to the corresponding sulfur compounds is also described. 
The literature references related to this work are provided at the end of the chapter. 
The second chapter deals with the synthesis and characterization of several 
selenium analogues of the antihypertensive drug captopril. The angiotensin converting 
enzyme (ACE) inhibition studies by captopril, its selenium analogue and a few 
derivatives by HPLC method are discussed. 
HPLC results suggest that the ACE inhibitory 
activity of the selenium analogue of captopril 
is similar to that of captopril. The orientation of the methyl group at the chiral center is 
very important for ACE inhibition. Both the chiral centers of the selenium analogue of 
captopril should be in (S,S)-configuration for an efficient inhibition of the enzyme. The 
selenium center in these compounds should be in selenol form for binding to the active 
site zinc(II) ion of the enzyme. The spacer between the selenol moiety and the proline 
residue also plays a vital role in ACE inhibition. The antioxidant behavior of captopril 
and its selenium analogues was studied as their ability to inhibit peroxynitrite-mediated 
nitration of angiotensin II and protein bovine serum albumin (BSA). It was observed that 
the selenium compounds are better scavengers of peroxynitrite than the sulfur-containing 
compounds. Although captopril was found to be a slightly better inhibitor of ACE than 
its selenium analogue, the antioxidant activity of the selenium compound was found to 
be higher than that of captopril. 
 In the third chapter, synthesis and characterization of Sec-Pro and Cys-Pro 
dipeptides are discussed. Angiotensin converting enzyme (ACE) inhibition studies by 
these dipeptides are also discussed. The ACE inhibition properties of these dipeptides 
suggest that the 
stereochemistry of the 
selenocysteine residue 
plays a key role in ACE 
inhibition. Replacement of the methyl group of the selenium analogue of captopril with 
the polar amino group significantly reduces the ACE inhibition potency. However, the 
presence of amino functional group oriented in the other direction (R-configuration) 
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enables the dipeptide to inhibit ACE. In the case of dipeptides, it is observed that the 
selenium analogues are better inhibitors of ACE as compared to the sulfur-containing 
compounds. The proline moiety is also important for ACE inhibition as a dramatic 
reduction in ACE inhibition is observed when the five membered ring of proline is 
replaced with a six membered ring. The terminal carboxylic functional group of proline 
residue in carboxylate form was also found to be important. Sec-Pro dipeptides were 
found to be better antioxidant than the Cys-Pro dipeptides in the inhibition of PN-
mediated nitration reactions of Ang II and BSA. 
Fourth chapter deals with the synthesis and characterization of captopril and its 
selenium analogue having an additional amino acid residue attached to the proline 
moiety. ACE inhibition studies by these compounds are discussed. From the ACE 
inhibition studies it is observed that the enzyme inhibition activity of the selenium 
analogue of captopril decreases 
upon substitution of an 
additional amino acid residue to 
the proline moiety. However, 
introduction of a phenylalanine 
residue does not alter the ACE inhibition potency of the selenium analogue of captopril. 
It is observed that the selenium compounds are better inhibitors of ACE than the sulfur 
analogues. The antioxidant behavior of these compounds was studied by using these 
compounds as scavengers of PN. These studies suggest that the antioxidant activity of 
these compounds does not depend on the substitution at the proline moiety, but it 
depends on the presence of the selenium or sulfur center. Selenium compounds are better 
scavengers of peroxynitrite in their diselenide form, whereas thiols are better PN 
scavenger than the corresponding disulfides. 
In the fifth chapter, synthesis and characterization of a few tripeptides 
containing selenocysteine or cysteine at the N-terminal end are discussed. Angiotensin 
converting enzyme (ACE) inhibition studies by these compounds are also discussed. It is 
observed that the ACE inhibition activity of the L-Sec-L-Pro dipeptides is slightly 
enhanced when a phenylalanine residue is attached to the C-terminal of proline. 
However, a dramatic reduction in ACE inhibition potency is observed when 
phenylalanine is replaced by valine or alanine residue. Cys-Pro-Phe tripeptide is an 
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efficient inhibitor of ACE. However, the selenium 
compounds are better ACE inhibitors than the sulfur 
analogues. The proline moiety is essential for ACE 
inhibition as the Cys-Val-Phe peptide does not show 
significant inhibition. As discussed in the previous chapters, 
the antioxidant behavior of these compounds was studied 
using peroxynitrite-mediated nitration of angiotensin II. These studies reveal that the 
antioxidant activity of these compounds depends on the presence of the Sec or Cys 
residues. 
In the sixth chapter, lactoperoxidase (LPO)-catalyzed iodination of human 
angiotensin I and II is described. It is observed that heme-peroxidases such as 
lactoperoxidase can effectively and selectively iodinate the tyrosyl residues in 
angiotensin peptides. The commonly used thiourea/thiouracil-based antithyroid drugs 
and the anti-hypertensive drug and angiotensin converting enzyme (ACE) inhibitor, 
captopril, effectively inhibit the iodination reactions, indicating that these compounds 
may have significant effect on the halogenation of angiotensins and related peptides by 
heme peroxidases. Inhibition of peroxidases is important as they can nitrate the tyrosine 
residue in presence of nitrate ion in place of iodide ion and can lead to nitrosative stress 
conditions. This study also shows that the monoiodo Ang I is a better substrate for ACE 
than the native peptide. As the monoiodo Ang II is a more potent pressor agent than the 
native hormone, both the direct iodination of Ang II and the efficient hydrolysis of the 
monoiodo Ang I by ACE could lead to an increase in blood pressure. Peroxynitrite-
mediated nitration and the site of nitration of Ang II peptide with mass spectrometry are 
also discussed. 
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